Myocarditis clinical trials at University of California Health
2 in progress, 1 open to eligible people
Abatacept in Immune Checkpoint Inhibitor Myocarditis
open to eligible people ages 18 years and up
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
MYTHS - MYocarditis THerapy With Steroids
Sorry, not currently recruiting here
This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).
Our lead scientists for Myocarditis research studies include Eric Yang, MD.